CB-NK-TGF-βR2-/NR3C1 / UT MD Anderson Cancer Center - LARVOL DELTA

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Suspended ➔ Active, not recruiting

Combination therapy • Enrollment closed • Minimal residual disease • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (clinicaltrials.gov) - P1 | N=15 | Suspended | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Suspended

Combination therapy • Minimal residual disease • Trial suspension • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Jun 2023 ➔ Feb 2027 | Trial primary completion date: Jun 2023 ➔ Feb 2027

Combination therapy • Minimal residual disease • Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Minimal residual disease • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor